Unique Ingredient Identifier J2B2A4N98G is listed as a unspecified ingredient
| NCIT | C28166 |
| RXCUI | 6211 |
UNII J2B2A4N98G LACTOSE, UNSPECIFIED FORM is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| BUCCAL | TABLET | 183.3 MG |
| BUCCAL/SUBLINGUAL | TABLET | 296.7 MG |
| IM - IV | INJECTION | 20.35 % |
| IM - IV | POWDER, FOR INJECTION SOLUTION | NA |
| IM - IV - SC | INJECTION | NA |
| IM - IV - SC | POWDER, FOR INJECTION SOLUTION | 13.3 % |
| INHALATION | CAPSULE | 20 MG |
| INHALATION | CAPSULE, HARD GELATIN | 25 MG |
| INHALATION | POWDER | 9 % |
| INHALATIONPOWDER, METERED | POWDER, METERED | 870 MG/1GM |
| INTRACAVITARY | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 19.38 % |
| INTRAMUSCULAR | INJECTION | NA |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION | 2 % |
| INTRAVENOUS | INJECTION | 1 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 5 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 10 % |
| IV(INFUSION) | SOLUTION, INJECTION | 0.45 % |
| ORAL | CAPSULE | 530 MG |
| ORAL | CAPSULE, COATED PELLETS | 102.44 MG |
| ORAL | CAPSULE, DELAYED ACTION, ENTERIC COATED | NA |
| ORAL | CAPSULE, ENTERIC COATED PELLETS | 231.84 MG |
| ORAL | CAPSULE, HARD GELATIN | 100 MG |
| ORAL | CAPSULE, SOFT GELATIN | 115.75 MG |
| ORAL | CAPSULE, SUSTAINED ACTION | 120 MG |
| ORAL | CONCENTRATE | NA |
| ORAL | GRANULE | 650.75 MG/5ML |
| ORAL | GRANULE, FOR SUSPENSION | NA |
| ORAL | POWDER, FOR SOLUTION | NA |
| ORAL | SOLUTION | 1682 MG/15ML |
| ORAL | TABLET | 2217 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 117.7 MG |
| ORAL | TABLET, COATED | 332.05 MG |
| ORAL | TABLET, CONTROLLED RELEASE | 0.017 MG |
| ORAL | TABLET, DELAYED ACTION | 92.02 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 209 MG |
| ORAL | TABLET, DELAYED RELEASE | NA |
| ORAL | TABLET, EXTENDED RELEASE | 122.99 MG |
| ORAL | TABLET, FILM COATED | 590 MG |
| ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 122 MG |
| ORAL | TABLET, REPEAT ACTION | 153.2 MG |
| ORAL | TABLET, SUSTAINED ACTION | 400 MG |
| ORAL | TABLET, SUSTAINED ACTION, FILM COATED | 51.1 MG |
| ORAL | TABLET, SUSTAINED RELEASE, FILM COATED | 38.75 MG |
| RECTAL | SOLUTION | 8 % |
| RECTAL | TABLET | 20 MG |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION | 2 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.5 % |
| SUBLINGUAL | TABLET | 175.92 MG |
| TOPICAL | EMULSION, CREAM | NA |
| TRANSDERMAL | FILM, CONTROLLED RELEASE | 675 MG |
| TRANSDERMAL | OINTMENT | 18.9 % |
| VAGINAL | EMULSION, CREAM | 3 % |
| VAGINAL | SUPPOSITORY | NA |
| VAGINAL | TABLET | 1013 MG |